Why is the Starpharma (ASX:SPL) share price trading at 52-week lows?

The biotech company has been in the doldrums lately.
The post Why is the Starpharma (ASX:SPL) share price trading at 52-week lows? appeared first on The Motley Fool Australia. –

Shares in biotechnology company Starpharma Holdings Limited (ASX: SPL) ended this week with another day in the red, trading 0.97% down at $1.02 at Friday’s close.

It’s been a lousy period for the company’s shareholders these past 3 months. The Starpharma share price hit its ceiling of $1.47 in late September and has since reversed course to trade at 52-week lows today.

Let’s take a closer look at what’s been happening for Starpharma in the past few weeks.

What’s up with Starpharma lately?

The market had a negative response to Starpharma’s FY21 results back in August. However, this was short lived, as investors bought in until lows of $1.15 and sent its share price back north. Shares then peaked in late September before reversing course and haven’t recovered since.

Interestingly, there wasn’t anything out of Starpharma’s camp that sent its shares flying south at the time. However, the biotech’s decline did correspond with a sector-wide selloff in ASX 200 health care shares.

Around the same time, on 23 September, the S&P/ASX 200 Health Care index (ASX: XHJ) tumbled from its high and lost more than 8% in a number of days.

The impulse of this selloff had a ripple effect into adjacent shares in the health care sector. However, just like the index, many of these names have recovered and are back at or near 3-months highs.

Starpharma is one exception to the pack and is instead hovering around its low-points. It isn’t attracting much investor attention either.

For instance, trading volume of Starpharma shares today is around 20% of their 4-week average of 610,683 shares.

What about the quarterly update?

The company released its quarterly trading update last month. It advised it had a cash balance of $53 million at quarter’s end, and had progressed its Viraleze pipeline.

Speaking on the report, Starpharma CEO Dr Jackie Farley said:

Starpharma continued to progress its three clinical stage DEP® assets, with a number of new and impressive tumour responses. Our partnered DEP® programs, including those with AstraZeneca, Merck and Chase Sun, are going well and we are really excited to see AZD0466 being presented by AstraZeneca at the ASH meeting in December.

The company is also set to launch its Viraleze label in Italy and Vietnam soon and has developed partnerships in doing so. Regarding the launch, Farley commented:

We are excited to see VIRALEZE launched in pharmacies and retail outlets in Italy and Vietnam soon. The overwhelming feedback from our distribution partners confirms the significant need for a product like VIRALEZE in addition to vaccines, and particularly for countries where vaccination rates are low.

We continue to progress negotiations for multiple other supply and distribution arrangements in further countries and regions, while we undertake international regulatory activities to expedite launch wherever possible. We look forward to announcing these commercial partnerships as they come on board.

Starpharma share price snapshot

The Starpharma share price is swimming in a sea of red across just about all time frames. In the past week, it is down almost 1.5%, and has lost 12% in the past month.

Over the last 12 months, Starpharma shares have decreased 23.5% after falling another 34.5% this year to date.

Each of these returns has lagged the benchmark S&P/ASX 200 index (ASX: XJO)’s return of around 13% in the previous year.

The post Why is the Starpharma (ASX:SPL) share price trading at 52-week lows? appeared first on The Motley Fool Australia.

These 5 Cheap Shares Could Be Set For Huge Gains (FREE REPORT)

We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can find out the names of these stocks in the FREE stock report.

*Extreme Opportunities returns as of February 15th 2021

More reading

Starpharma (ASX:SPL) share price lifts on supply and distribution deal

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!